Please select a Capability in order to start your service request.
Exhibit Offers Experiential View of BD’s Robust Portfolio from Preparation to AdministrationDec 8, 2014
FRANKLIN LAKES, N.J., December 8, 2014 – BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, is presenting its comprehensive solutions for the hospital pharmacy during the 49th American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting taking place December 7-11, 2014 at the Anaheim Convention Center in Orange County, California. Building on BD’s legacy and commitment to supporting safety and efficiency in healthcare, the solutions on display at Booth #1101 demonstrate a cohesive approach to reducing the possibility of human error, protecting healthcare workers from occupational hazards, standardizing practice, streamlining workflow and increasing efficiency from medication preparation to delivery.
“Despite best efforts, patient and healthcare worker safety can still be compromised during the medication distribution process,” said William A. Tozzi, President, BD Medical – Medical Surgical Systems. “Furthermore, as healthcare continues to evolve, there is an increasing demand for better outcomes, while still controlling costs by implementing smarter workflow efficiencies. BD’s robust portfolio of hospital pharmacy solutions is specifically designed to address these challenges by enhancing patient and healthcare worker safety, improving workflow efficiencies and helping to facilitate compliance to evolving guidelines and standards.”
The exhibit will provide an experiential view of BD’s solutions developed to help combat against the difficult task pharmacy practice leaders face in balancing quality improvements, compounding legislations changes and drug shortages while continuing to meet cost reduction expectations.
BD’s experiential Booth #1101 will showcase:
BD Cato™ Medication Workflow Solutions: an automated pharmacy workflow system that detects wrong dose/drug errors in real time, standardizes workflow for medication preparations, automates documentation and optimizes drug utilization to reduce drug waste. The system provides a robust interface with Pharmacy IT systems to automatically pull in medication orders and allow dose queue management within the preparation environment, and provides a range of reports and analytics to help improve safety and efficiency. This year, BD will be showcasing a new camera-based visual documentation system ahead of launch in February 2015, which will enable remote dose verification and image documentation.
BD Diabetes Care and AutoShield DuoBD: the BD AutoShield Duo pen needle is the only safety pen needle in the U.S. that provides both front and back end passive needle protection to lower the risk of accidental needlestick injuries, and supports the current AADE practice advisory for injection technique guidelines calling for the use of shorter needles, proper site rotation and using needles only one time. For 90 years, BD's culture of innovation and continuous improvement has enhanced the patient experience to help improve therapy and outcomes for people with diabetes worldwide.
BD Disposal Solutions: are collectors specifically designed to safely contain sharps, non-hazardous pharmaceutical, chemotherapy and hazardous RCRA waste. The collectors come in a variety of colors and sizes to meet disposal needs and are safe for incineration.
BD Enteral Syringe with BD UniVia™ Connector: is designed to reduce the risk of tubing set misconnections, which may lead to medication errors. This helps to safely deliver nourishment and oral medications.
BD Medication Preparation Products: including BD™ Filter and BD Nokor™ needles, BD Sterile Syringe Convenience Trays, BD Tip Cap Trays, BD Oral Syringe System and BD PosiFlush™ Pre-Filled Syringes are designed to enhance the medication preparation and delivery process.
BD PhaSeal™ System: a closed-system drug transfer device (CSTD) that reduces healthcare workers' exposure to hazardous, parenteral medications from preparation in the pharmacy to administration with the patient. The BD PhaSeal System is an airtight and leak-proof CSTD that mechanically prohibits the transfer of environmental contaminants into the system and the escape of drug or vapor concentrations outside the system, thereby minimizing individual and environmental exposure to drug vapor aerosols and spills. The system also prevents microbial ingress. With a limited number of components and only one connection interface, the BD PhaSeal System dimensions are created to ISO standards to be compatible with all standard size drug vials and tubing.
BD Simplist™ Prefilled Injectables: are ready-to-administer, prefilled injectables designed to reduce the potential risk of medication error. Individually packaged, clearly labeled and bar-coded ready-to-administer (RTA) injectables enable compliance with The Joint Commission Medication Management standards.
Intelliport® System: a medication management solution for manual IV bolus injections that automatically identifies the IV injectable drug name and concentration, performs real-time allergy checks before an injection, measures the cumulative dose being administered to a patient during an injection and wirelessly sends captured information on drug/dose/time directly into the patient’s electronic medical record following an injection. The Intelliport® System is currently under FDA review. Intelliport is a trademark of CRISI Medical Systems, Inc.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com
For more information on BD, please visit bd.com.